Ardelyx Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Highlights
Company well positioned for PDUFA date of April 29, 2021 and the potential launch of tenapanor
News provided by
Share this article
Share this article
FREMONT, Calif. and WALTHAM, Mass., March 8, 2021 /PRNewswire/ Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiorenal diseases, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2020. The stage is set for an exciting year for Ardelyx in 2021 said Mike Raab, president and chief executive officer at Ardelyx. With our PDUFA date of April 29 rapidly approaching, we are well positioned and well prepared to commercialize tenapanor upon potential FDA approval of the first and only phosphate absorption inhibitor for the control of serum phosphorus. In addition,
Worthing sepsis survivor launches podcast to raise awareness of life-threatening medical emergency
littlehamptongazette.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from littlehamptongazette.co.uk Daily Mail and Mail on Sunday newspapers.
Ardelyx Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Highlights
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.